Join us on 12-15-2022 for a live seminar about RNA SEQ

Click Here
Learn more

Enabling drug discovery technologies

Join the over 130 companies already working with one or more of Alloy’s technologies. License our proprietary, pre-competitive biologics drug discovery platforms invented by Alloy, pharma, academia, and within the Alloy ecosystem.

ANTIBODY DISCOVERY PLATFORMS

TCR DISCOVERY PLATFORMS

SUBSCRIPTION WITH UNLIMITED ACCESS

License the world’s most popular humanized mouse discovery platform

Alloy Therapeutics humanized mouse antibody drug discovery platforms

ATX-Gx™ is the most popular in vivo human antibody discovery platform with over 140 partners and counting. Originally invented and validated inside a major pharma company then further developed by Alloy, our foundational suite of highly immunocompetent transgenic mice is engineered to drive the greatest potential diversity of unique human antibodies binding to your target of interest, with broad epitopic coverage.

ACCESSIBLE TERMS

Simple licensing process enables partners to start working within two weeks, in their labs, or with our Antibody Discovery Services team. 

TOP IMMUNOCOMPETENCE

Comprehensive functional human antibody repertoire optimized for human antibody sequence developability and diversity. 

CONTINUOUS INNOVATION

All partners have access to our rapidly expanding portfolio of transgenic strains designed to address a range of discovery challenges.

Accessible Terms

Simple licensing process enables partners to start working within two weeks, in their labs or with our Antibody Discovery Services team. 

Highly Immunocompetent

Comprehensive functional human antibody repertoire is optimized for human antibody sequence developability and diversity.

Continuous Innovation

Partners automatically access our expanding portfolio of transgenic strains designed to address a range of discovery challenges. 

Empower your discovery with ATX-Gx

Get started with human antibody discovery in less than two weeks by licensing the ATX-Gx mouse platform, or we can do your discovery for you via Alloy’s services team and our proprietary, fully-integrated in vivo, in vitro, and in silico antibody discovery service, DeepImmune™.

License the ATX-Gx mouse
Learn about DeepImmune
next generation platforms

Enabling bispecifics, multispecifics, and single domain antibody discovery

We are always expanding our portfolio of innovative enabling discovery technologies. Get early access to our newest transgenic murine platforms: ATX-CLC for common-light chain bispecifics and multispecifics discovery and ATX-SiD for discovery of single domain antibodies.

Discuss licensing our newest platforms

ATX-CLC

Transgenic murine in vivo discovery platform optimized for bispecific and multispecific human antibody-based therapeutics. Available in later 2022. 

ATX-SiD

Transgenic murine in vivo discovery platform optimized for single-domain human antibody-based therapeutics. Available in 2023. 

TCR drug discovery services

FOR NEXT GENERATION IMMUNOTHERAPY

T-cell receptor discovery platforms

Keyway™ TCR Discovery is developing new technology platforms to help drugmakers reach the 90% of targets that aren’t accessible by conventional cancer immunotherapies. These technologies will be first accessible through Keyway TCR Discovery Services to discover custom, therapeutic TCR mimics (TCRm) and engineered TCRs against your targets of interest. All Keyway platforms are available via platform transfer and as part of an Innovation Subscription.

Go to Keyway TCR Discovery services

All-access
innovation subscriptions

Get unlimited access to all our current and future technology for one fixed annual fee, with no Alloy milestones or royalties.

Schedule an Innovation Subscriptions call

Find the best drug candidate against your target

We develop technologies and services across 6 drug modalities in our R&D facilities around the world and through our collaborations. Today partners can license technologies and access discovery services in Antibodies and TCRs. Click the icons below to learn about our approach in each modality, and please reach out to our team if you’re interested in collaborating on the development of new technology that can be shared with the world.
antibody drug discovery
ANTIBODIES
TCR drug discovery

TCRS

ASO genetic medicines discovery
GENETIC MEDICINES
peptides drug discovery
PEPTIDES
Cell therapies
CELL THERAPIES
biologics drug delivery
DELIVERY

Stay up to date as we expand our platforms and services

Join our email list
Accept Privacy Settings Here
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please read and Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound
Save
We use cookies to enhance your experience while using our website. To learn more about the cookies we use and the data we collect, please read and Accept Privacy Settings Here.
I Accept